CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more
CERENO SCIENTIFIC AB B (4A1) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CERENO SCIENTIFIC AB B - Net Assets Trend (None–None)
This chart illustrates how CERENO SCIENTIFIC AB B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CERENO SCIENTIFIC AB B (None–None)
The table below shows the annual net assets of CERENO SCIENTIFIC AB B from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to CERENO SCIENTIFIC AB B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
CERENO SCIENTIFIC AB B Competitors by Market Cap
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Gooch & Housego PLC
PINK:GCHHF
|
$130.48 Million |
|
Geospace Technologies Corporation
NASDAQ:GEOS
|
$130.55 Million |
|
Axtel S.A.B. de C.V
OTCGREY:AXTLF
|
$130.56 Million |
|
Zhejiang Jindao Technology Co. Ltd.
SHE:301279
|
$130.56 Million |
|
Zalaris ASA
OL:ZAL
|
$130.41 Million |
|
Innova Captab Limited
NSE:INNOVACAP
|
$130.37 Million |
|
Locaweb Serviços de Internet S.A.
SA:LWSA3
|
$130.33 Million |
|
BioPorto A/S
PINK:THOXF
|
$130.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CERENO SCIENTIFIC AB B's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares CERENO SCIENTIFIC AB B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently CERENO SCIENTIFIC AB B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares CERENO SCIENTIFIC AB B's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CERENO SCIENTIFIC AB B (4A1) | €- | N/A | N/A | $130.44 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |